Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kawaguchi T, Ando M, Asami K, Okano Y, et al. Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014 May 19. pii: JCO.2013.52.4694.
PMID: 24841974

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016